On April 16, 2025, Psyence Biomedical Ltd. shareholders approved a 50-for-1 reverse stock split, with 95.78% voting in favor. Additionally, the Nasdaq notified the company of its non-compliance with listing rules due to share prices below the $1.00 threshold for 30 consecutive days, triggering a potential delisting process.